Latest revenue
$190.0K
as of 2025-09-30
Latest net income
$-25.7M
as of 2025-09-30
Net margin
-13549.5%
as of 2025-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ATYR is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $46.1M
- Enterprise value
- $39.9M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.80×
- Dividend yield
- 0.0%
- 52-wk high
- $7.29
- 52-wk low
- $0.40
- Beta
- —
- Shares out
- 98.1M
5-year trend
What this company does
Item 1. Business. We are a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. Our discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by our proprietary library of domains derived from all 20 tRNA synthetases. Efzofitimod Our lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD),…
AI summary unavailable — showing raw filing excerpt
Generated from ATYR's filing dated 2026-03-05
Key risks
Item 1A. Risk Factors You should carefully consider the following risk factors, as well as the other information in this Annual Report on Form 10-K (Annual Report) and in our other public filings with the SEC. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report and those we may make from time to time. You should consider all of the risk factors described in our public filings when evaluating our business. Risks related to the discovery, development and regulation of our product…
AI summary unavailable — showing raw filing excerpt
Generated from ATYR's filing dated 2026-03-05
Profitability
Operating margin
-40856.3%
41.4%Net margin
-39009.5%
43.2%Return on equity
-109.8%
20.1%Return on assets
-79.7%
20.5%Leverage
Debt / equity
0.38×
1.2%Long-term debt / equity
0.00×
69.7%Debt / assets
27.4%
0.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-10.8M | +27.5% | — |
Q4 2025 2025-12-31 | $0 | — | $-14.0M | +6.7% | — |
Q3 2025 2025-09-30 | $190.0K | — | $-25.7M | -49.2% | -13549.5% |
Q2 2025 2025-06-30 | $0 | — | $-19.5M | -19.8% | — |
Q1 2025 2025-03-31 | $0 | -100.0% | $-14.9M | +3.9% | — |
Q4 2024 2024-12-31 | $0 | — | $-15.0M | — | — |
Q3 2024 2024-09-30 | $0 | -100.0% | $-17.3M | -52.2% | — |
Q2 2024 2024-06-30 | $0 | — | $-16.3M | -32.2% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on ATYR — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$911.8K
Insider selling
$6.3K
Net activity
+$905.5K
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ATYR
Institutional value
$21.5M
Total shares held
29.3M
Distinct holders
64
-19 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | FEDERATED HERMES, INC. | 10.5M | $8.2M | +0 (+0.0%) | No change |
| 2 | BlackRock, Inc. | 6.4M | $5.0M | -105.8K (-1.6%) | Trimmed |
| 3 | UBS Group AG | 3.9M | $3.0M | +2.2M (+137.9%) | Added |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3.8M | $3.0M | — | New |
| 5 | VANGUARD FIDUCIARY TRUST CO | 651.8K | $508.4K | — | New |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 569.2K | $444.0K | — | New |
| 7 | Nuveen, LLC | 229.3K | $178.8K | +1.3K (+0.6%) | Added |
| 8 | Bank of New York Mellon Corp | 193.5K | $151.0K | -1 (-0.0%) | Trimmed |
| 9 | GROUP ONE TRADING LLC | 184.0K | $143.5K | -7.0K (-3.7%) | Trimmed |
| 10 | DEUTSCHE BANK AG\ | 103.3K | $80.6K | -17.0K (-14.1%) | Trimmed |
| 11 | RHUMBLINE ADVISERS | 103.1K | $80.4K | +3.4K (+3.4%) | Added |
| 12 | HOHIMER WEALTH MANAGEMENT, LLC | 100.0K | $78.0K | — | New |
| 13 | DIMENSIONAL FUND ADVISORS LP | 91.9K | $71.5K | -5.6K (-5.8%) | Trimmed |
| 14 | KINGSWOOD WEALTH ADVISORS, LLC | 52.0K | $40.6K | +0 (+0.0%) | No change |
| 15 | Redhawk Wealth Advisors, Inc. | 49.1K | $38.3K | — | New |
| 16 | JANE STREET GROUP, LLC | 48.5K | $37.8K | -139.6K (-74.2%) | Trimmed |
| 17 | WELLS FARGO & COMPANY/MN | 46.5K | $36.3K | -70.2K (-60.1%) | Trimmed |
| 18 | Invesco Ltd. | 46.4K | $36.2K | +121 (+0.3%) | Added |
| 19 | Belpointe Asset Management LLC | 45.7K | $35.7K | +35.3K (+338.2%) | Added |
| 20 | JPMORGAN CHASE & CO | 42.0K | $30.7K | -68.4K (-62.0%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ATYR's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.